SB 01

Drug Profile

SB 01

Alternative Names: BPR 0L075; DBPR104; SB01; SCB 01A

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Health Research Institutes
  • Developer SynCore Biotechnology
  • Class Antineoplastics; Indoles; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Taiwan (Parenteral, Injection)
  • 18 Oct 2017 SynCore Biotechnology terminates a phase II trial for Head and neck cancer (Inoperable/unresectable, Recurrent, Metastatic disease, Second-line therapy or greater) in Taiwan (NCT02488629)
  • 11 Jul 2017 SynCore Biotechnology completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in Taiwan (IV) (NCT01159522)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top